Clinician walkthrough

Cardiometabolic Risk Assessment with Standard Labs

A page-by-page look at the report your patient receives: what each score measures, where it comes from, and how to use it in a visit. The patient sees the same pages with plain-language explanations; this guide adds the methods and evidence behind them.

What goes into the report

  • Quest Diagnostics fasting panel: standard lipid panel, ApoB (Cardio IQ), lipoprotein(a), hs-CRP, fasting glucose and insulin, hemoglobin A1C, and a basic metabolic panel including eGFR. The liver screening also requires AST, ALT, and a platelet count.
  • Pre-assessment survey: anthropometrics and blood pressure, medications, smoking, family history, prior cardiovascular testing and events, familial hypercholesterolemia features, and the conditions that count as risk-enhancing factors.
  • Guideline frameworks: AHA PREVENT equations, the risk-enhancing factors in the 2026 AHA/ACC/NLA cholesterol guideline, harmonized metabolic syndrome criteria, the MetS severity score from MetS Calc, AHA CKM staging, and FIB-4 thresholds from AGA/AASLD guidance.

HOMA-IR requires fasting glucose and insulin, so the draw must be fasting.

Reading the scales

Every scale runs green (lower risk) to red (higher risk). Category labels follow the source guideline or model, so they differ by domain:

DomainCategories
HOMA-IR (0.5–4.5)Optimal, Near Optimal, Intermediate, High, Very High
MetS severity percentile; PREVENT 10- and 30-yearLow, Borderline, Intermediate, High
5-year T2D risk; overall CV riskLow, Moderate, High, Very High
Hemoglobin A1CNormal, Pre-Diabetes, Diabetes
FIB-4Low (<1.3), Indeterminate, High (>2.67)
CKM stageStage 0–4

A white circle marks the current value; an X marks a category result. In follow-up reports a gray box marks the baseline value. In the metabolic syndrome table, yellow cells meet a criterion and red cells flag hs-CRP or ApoB above the high-risk cutoff. On the CKM page, each factor is marked Present, —, or Not assessed.

Methods at a glance

Each score in the report comes from a published method or guideline. The one exception is how the overall cardiovascular risk category combines PREVENT with risk-enhancing factors, which is our own method.

MeasureHow it is derivedRefs
HOMA-IRHomeostatic model assessment of insulin resistance: fasting insulin (µIU/mL) × fasting glucose (mg/dL) ÷ 405. The scale’s hash marks sit at the 5th, 25th, 50th, 75th, and 95th percentiles for the patient’s sex and ethnicity, adjusted for whether fasting glucose and A1C agree.Matthews DR, et al. Diabetologia 1985
5-year T2D riskSex-specific probability of incident type 2 diabetes from a Precision Health Reports model developed by our Chief Medical Officer, integrating A1C, fasting glucose, and HOMA-IR. Displayed against A1C with curves for the 5th and 95th percentiles of HOMA-IR.Internal model
MetS severity scoreSex- and race/ethnicity-specific continuous score from a confirmatory factor analysis of the five MetS components in NHANES adults, calculated with MetS Calc (metscalc.org). It behaves like a z-score and is reported as a percentile of U.S. adults. Higher scores predict incident diabetes, coronary heart disease, CVD, and ischemic stroke.9–16
Metabolic syndromeHarmonized criteria: waist above the sex- and ethnicity-specific cutoff, BP ≥130/85, fasting glucose ≥100, triglycerides ≥150, HDL-C <40 (men) or <50 (women), or drug treatment for that factor. Three or more criteria means metabolic syndrome.7, 8
PREVENT riskAHA PREVENT equations: 10-year and 30-year risk on the cardiovascular page, and 10-year total CVD risk for the CKM Stage 3 threshold, from the patient’s labs (including eGFR) and survey data.Khan SS, et al. Circulation 2024
Overall CV riskCombines calculated PREVENT risk with every risk-enhancing factor in the 2026 AHA/ACC/NLA cholesterol guideline that applies to the patient, from labs, imaging history, and survey answers.—
Lipoprotein goalsFor the patient’s overall risk category, each LDL-C, non-HDL-C, and ApoB threshold goal is the lower of the guideline’s recommended percent reduction from baseline or its absolute target. ApoB is emphasized because particle number tracks risk reduction more closely than cholesterol content.17–22, 29, 30
hs-CRPHigh-sensitivity C-reactive protein. Values above 3.0 mg/L are flagged as a high-risk metabolic syndrome factor, consistent with AHA/CDC risk categories.Pearson TA, et al. Circulation 2003
FIB-4(Age × AST) ÷ (platelets × √ALT). <1.3 low and >2.67 high risk of advanced fibrosis, with a higher low-risk cutoff at age 65 and older. Not validated below age 35, so the page is omitted for younger patients.Sterling 2006; AGA 2021; AASLD 2023
CKM stageAHA CKM staging, 0 to 4, set by the highest stage with at least one factor present, using report labs, PREVENT, and survey history. Kidney risk uses the KDIGO eGFR and albuminuria categories and reads “Not assessed” unless the optional urine albumin test was ordered.Ndumele 2023

Page by page

Click any sample page to see it larger. The sample is an initial report. The liver page is included by default; it is omitted if the ordering organization removes it or the patient is younger than 35, and later pages shift up by one.

Sample page: Cover
Page 1

Cover

Patient, report date, and ordering provider.

  • Identifies the patient and the ordering clinician or organization
  • Frames the report as decision support for shared decision-making, not a substitute for it
Click anywhere to close
Sample page: Letter from the Chief Medical Officer
Page 2

Letter from the Chief Medical Officer

Sets the patient’s mental model before the numbers.

  • Presents insulin resistance as the common driver of metabolic syndrome, type 2 diabetes, and ASCVD
  • Explains that personal risk goes beyond major risk factors and population equations, and includes more than 30 guideline risk-enhancing factors
  • Emphasizes that risk is modifiable and that response should be tracked with retesting
It gives you and the patient a shared starting point: what is driving insulin resistance, and what to change first.
Click anywhere to close
Sample page: Cardiometabolic Risk Summary
Page 3

Cardiometabolic Risk Summary

Five risk domains on one page for quick triage.

  • HOMA-IR, the report’s anchor for insulin resistance
  • MetS severity percentile, with category boundaries at the 25th, 50th, and 75th percentiles
  • 5-year type 2 diabetes risk, with category boundaries at 5%, 10%, and 20%
  • Overall cardiovascular risk category, from Low to Very High, after risk-enhancing factors are applied
  • CKM stage, 0 to 4, detailed on page 8
Look for discordance. A high HOMA-IR with normal glucose and A1C flags insulin resistance years before dysglycemia. A Low PREVENT result with a High overall category means risk-enhancing factors are moving the patient up, and the cardiovascular page shows which ones.
Key references: 9, 17
Click anywhere to close
Sample page: Metabolic Risk Details
Page 4

Metabolic Risk Details

Insulin resistance, metabolic syndrome criteria, and severity.

  • HOMA-IR from fasting glucose and insulin, plotted against percentile hash marks specific to the patient’s sex and ethnicity.
  • The five metabolic syndrome criteria with sex- and ethnicity-specific waist cutoffs. Criteria met are shaded yellow, and treatment for a factor counts as meeting it.
  • Two additional high-risk factors shaded red when exceeded: hs-CRP >3.0 mg/L and ApoB >110 mg/dL
  • MetS severity score (MetS Calc), reported as a sex- and race/ethnicity-specific percentile of U.S. adults. Unlike the yes/no diagnosis, it captures severity below the diagnostic threshold and changes with treatment.
Because the severity score is continuous, it can show improvement from weight loss, activity, or treatment of individual components even when the yes/no criteria count doesn’t change.
Key references: 7–16
Click anywhere to close
Sample page: Diabetes Risk Details
Page 5

Diabetes Risk Details

Current glycemic status and forward-looking diabetes risk.

  • Hemoglobin A1C on a Normal, Pre-Diabetes, and Diabetes scale, with breakpoints at 5.7% and 6.5%
  • HOMA-IR with its category scale
  • 5-year probability of incident type 2 diabetes plotted against A1C, with curves for the 5th and 95th percentiles of HOMA-IR
  • Risk bands are labeled by intervention intensity, from minimal (low risk) to maximum (very high risk), so the chart doubles as a counseling tool
Lifestyle change, weight loss, and metformin have all been shown to improve insulin resistance, which gives you a lever to retest and show the patient.
Key references: 23–28
Click anywhere to close
Sample page: Liver Fibrosis Details (FIB-4)
Page 6 · Default

Liver Fibrosis Details (FIB-4)

Noninvasive screening for advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD).

  • Shows the inputs (age, AST, ALT, platelets) and the FIB-4 score on a Low, Indeterminate, and High scale with cutoffs at 1.3 and 2.67; the low-risk cutoff is raised for patients 65 and older
  • Plain-language interpretation and a recommended next step for the patient to discuss with you
  • Notes that advanced fibrosis is an emerging cardiovascular risk enhancer. The FIB-4 result itself does not feed the cardiovascular risk calculation, but a reported MASLD diagnosis is counted as a risk-enhancing factor.
  • Included by default; omitted when the ordering organization removes it or the patient is younger than 35, where FIB-4 is not validated
Indeterminate or High? Current AGA and AASLD pathways recommend a second-line test, such as vibration-controlled transient elastography or the ELF test, to clarify fibrosis risk before referral.
Sources: Sterling RK, et al. Hepatology 2006 (FIB-4 derivation); AGA Clinical Care Pathway (Kanwal F, et al. Gastroenterology 2021); AASLD Practice Guidance (Rinella ME, et al. Hepatology 2023)
Click anywhere to close
Sample page: Cardiovascular Risk Details
Page 7

Cardiovascular Risk Details

Calculated risk, risk-enhancing factors, overall category, and lipoprotein goals.

  • PREVENT 10-year risk with categories at 3%, 5%, and 10%, and 30-year risk with categories at 10%, 19%, and 24%. The report notes that lipid-lowering therapy is recommended at a 10-year risk of 5% or more, or a 30-year risk of 10% or more.
  • Clinical risk-enhancing factors present for this patient, drawn from labs (such as LDL-C, non-HDL-C, ApoB, Lp(a), and hs-CRP), imaging history (such as a CAC score), and survey conditions (including family history, sleep apnea, and sex-specific factors)
  • Overall cardiovascular risk category, from Low to Very High, combining PREVENT with all applicable risk-enhancing factors in the 2026 AHA/ACC/NLA guideline
  • Personalized LDL-C, non-HDL-C, and ApoB threshold goals for that category, shown next to baseline and current values. Each goal is the lower of the recommended percent reduction from baseline or the absolute target.
ApoB is the primary target. When LDL-C and ApoB disagree, which is common with insulin resistance and high triglycerides, ApoB better reflects the atherogenic particle burden and the risk reduction from therapy.
Key references: 17–22, 29, 30
Click anywhere to close
Sample page: Cardiovascular-Kidney-Metabolic (CKM) Stage
Page 8

Cardiovascular-Kidney-Metabolic (CKM) Stage

AHA CKM staging, with every factor shown so the stage is transparent.

  • Stage scale 0–4 with the patient’s stage marked, then a factor table grouped by stage: threshold, patient value, and status (Present, —, or Not assessed)
  • Stage 1: excess or dysfunctional adiposity (BMI ≥25 or waist above threshold) and prediabetes (fasting glucose ≥100 or A1C ≥5.7%)
  • Stage 2: blood pressure ≥130/80 or treated, triglycerides ≥135 mg/dL or treated, diabetes, metabolic syndrome, and KDIGO moderate- or high-risk CKD. Self-reported familial hypercholesterolemia is listed as a major risk factor, though it is not a standard CKM criterion.
  • Stage 3: subclinical atherosclerosis (CAC >99 or ≥75th percentile), diagnosed LVH, stage 3–4 CKD, KDIGO very-high-risk CKD, or PREVENT 10-year total CVD risk ≥20%
  • Stage 4: clinical ASCVD (MI, stroke or TIA, angina, claudication, revascularization), heart failure, atrial fibrillation, or aortic aneurysm
  • Footnotes explain where CKM thresholds are stricter than the metabolic syndrome criteria, and when BMI may overstate adiposity because waist circumference is normal
Kidney rows usually read “Not assessed.” KDIGO risk categories need both eGFR and albuminuria, and a urine albumin-to-creatinine ratio (uACR) is an optional add-on that most orders don’t include. Without it, the stage reflects the other CKM factors.
Sources: Ndumele CE, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation 2023; KDIGO 2024 CKD Guideline
Click anywhere to close
Sample page: Additional Topics for Discussion
Page 9

Additional Topics for Discussion

Narrative talking points generated from the patient’s results and survey.

  • Short explanations of findings that warrant discussion, such as severely elevated LDL-C or ApoB, high Lp(a), elevated hs-CRP, or whether noninvasive imaging may be a reasonable next step
  • Links to patient education pages for each topic, and to the reference list
This page differs for every patient, so it is a good agenda for the visit.
Click anywhere to close
Sample page: Tracking Charts
Pages 10–13

Tracking Charts

Serial values against goals, designed for retesting.

  • Metabolic risk tracking: the five MetS components, the severity score, and hs-CRP at each test
  • Diabetes risk tracking: A1C, fasting glucose, HOMA-IR, and estimated 5-year risk
  • Atherogenic lipoprotein tracking: LDL-C, non-HDL-C, and ApoB against each threshold goal
  • A QR code on the divider page links the patient to a reference page for every topic in the report
An initial report shows one data point per chart. Each follow-up adds a point, which makes response to therapy visible to the patient.
Click anywhere to close
Sample page: Pre-Assessment Survey Responses
Pages 14–15

Pre-Assessment Survey Responses

Every patient-reported input that feeds the calculations.

  • Height, weight, waist, BMI, and blood pressure, which drive the MetS criteria, MetS severity score, PREVENT, and CKM stage
  • Blood pressure and glucose history and treatment, smoking, and family history of diabetes and premature ASCVD
  • Prior vascular testing (CAC, CTA, carotid ultrasound, ABI, angiography) and any events or procedures
  • LDL-C history and familial hypercholesterolemia features, current lipid therapy, and conditions that count as risk-enhancing factors, including sex-specific factors
Worth a quick review. Self-reported waist, blood pressure, and history can change a MetS criterion, the PREVENT estimate, the overall category, or the CKM stage. If an entry looks wrong, confirm it with the patient, because the affected results depend on it.
Click anywhere to close
Sample page: Quest Diagnostics Lab Report
Final pages

Quest Diagnostics Lab Report

The complete Quest Diagnostics report, unaltered.

  • Standard lipid panel (LDL-C by the Martin-Hopkins calculation)
  • Cardio IQ ApoB and lipoprotein(a)
  • hs-CRP, fasting glucose and insulin, and hemoglobin A1C
  • Basic metabolic panel, including eGFR
Lab flags use Quest Diagnostics’s general reference intervals. The threshold goals in the report are individualized and usually stricter.
Click anywhere to close

Follow-up reports

Follow-up reports keep the same structure and add the patient’s baseline beside each current value.

  • On every scale, a gray box marks the baseline value and a white circle marks the current value
  • Detail tables show baseline and current columns, colored by the same criteria
  • Lipoprotein threshold goals stay anchored to the baseline values, so percent-reduction goals don’t drift as values improve
  • Tracking charts add a point for each test. The report suggests reassessing every 3 to 6 months, depending on risk.

See it with your own patients

Ordering takes about 30 seconds, and we deliver the completed report in a few days. We’re happy to walk through a sample with you.

Book a call

Sample pages have all personal details removed. Reference numbers match the list on our references page. Precision Health Reports supports, and does not replace, clinical judgment.